Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;165(2):405-415.
doi: 10.1002/ijgo.15148. Epub 2023 Sep 29.

Quality testing of mifepristone and misoprostol in 11 countries

Jason Bower  1 , Lester Chinery  2 , Alessandra Fleurent  2 , A Metin Gülmezoglu  2 , Wallada Im-Amornphong  2 , Catherine Kilfedder  3 , Petra Procter  2 , Alessandra Tomazzini  2
Affiliations

Quality testing of mifepristone and misoprostol in 11 countries

Jason Bower et al. Int J Gynaecol Obstet. 2024 May.

Abstract

Objective: Previous studies have demonstrated quality concerns with misoprostol. Mifepristone, however, has not been extensively assessed for quality. Between 2020 and 2021, Concept Foundation and the International Planned Parenthood Federation conducted a study to determine the quality of these medical abortion drugs in low- and middle-income countries (LMIC).

Methods: The collection of batch samples of misoprostol and mifepristone was carried out by trained sampling agents in selected LMIC. Single drug packs and combipacks were sampled. A World Health Organization prequalified laboratory conducted testing method verifications and subsequent sample analysis. Tests included identification, assay, related substances, and content uniformity for misoprostol, and identification, assay, related substances, and dissolution for mifepristone.

Results: Samples were collected from Burkina Faso, Cambodia, Democratic Republic of Congo, India, Kyrgyzstan, Moldova, Nepal, Nigeria, Pakistan, Uganda and Vietnam. Sixty-four pooled batch samples were tested, consisting of 31 combipacks, 26 misoprostol-only and seven mifepristone-only products. Overall, 54.7% of samples were non-compliant with one or more of the specifications, representing 51.6% of combipack products, 57.1% of misoprostol tablets analyzed and 23.7% of mifepristone tablets. One falsified misoprostol-only product was found.

Conclusion: The present study confirms that a significant problem still exists in relation to the quality of medical abortion drugs in LMIC. For misoprostol, our findings suggest that historical concerns around primary packaging may have been largely resolved but that manufacturing processes for both finished product and active pharmaceutical ingredient need to be improved. The present study also provides evidence of mifepristone quality issues.

Keywords: falsified medicine; medical abortion; medicine quality; mifepristone; misoprostol; pharmaceutical analysis; quality survey; substandard medicine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

REFERENCES

    1. World Health Organization. Abortion [WHO website]. Accessed May 31, 2023. https://www.who.int/health‐topics/abortion
    1. World Health Organization. Abortion care guideline. World Health Organization; 2022.
    1. World Health Organization. WHO Model List of Essential Medicines, 21st List, 2019. World Health Organization; 2019.
    1. World Health Organization. WHO Consolidated Guideline on Self‐Care Interventions for Health: Sexual and Reproductive Health and Rights. World Health Organization; 2019.
    1. World Health Organization. WHO Recommendations on Self‐Care Interventions: Self‐Management of Medical Abortion, 2022 Update. World Health Organization; 2022.

LinkOut - more resources